Dec 30, 2025 • ts2.tech
SOMEWHAT-BEARISH
Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus
Rhythm Pharmaceuticals (RYTM) shares dropped today as the biotech sector weakened, with major biotech ETFs down over 1%. Investors are keenly awaiting the FDA's decision on a label expansion for Rhythm's obesity drug, Imcivree, for acquired hypothalamic obesity, with a new review deadline set for March 20, 2026. The company also faces competition in the Prader-Willi syndrome landscape and is preparing for Phase 3 trials and future updates.
Dec 30, 2025 • The Business Journals
NEUTRAL
Biotech pioneer who helped launch Biogen dies at 94
Charles Weissmann, co-founder of Biogen, has passed away at the age of 94. His significant contributions to biotechnology in the late 1970s paved the way for new treatments for conditions like hepatitis and leukemia. Weissmann's legacy is marked by his groundbreaking work that fundamentally changed therapeutic possibilities in the biotech industry.
Dec 30, 2025 • Insider Monkey
SOMEWHAT-BULLISH
Strong Results and Pipeline Momentum Power Amgen’s (AMGN) 2025 Rally
Amgen Inc. (NASDAQ: AMGN) has seen a strong rally in 2025, with its stock up over 27%, driven by robust financial results and significant progress in its clinical pipeline. The company reported a 12% increase in Q3 revenue, reaching $9.6 billion, with key products like Repatha and Tezspire showing substantial sales growth. Despite anticipated competition for its bone-health drugs, Amgen's promising pipeline, including the MariTide weight management program in Phase 3 studies, and a consistent dividend history, support its positive outlook.
Dec 30, 2025 • Citeline News & Insights
NEUTRAL
Genmab Pulls Plug On Acasunlimab Development In Pipeline Reset
Genmab has decided to discontinue the development of Acasunlimab as part of a pipeline reset. This decision comes after their recent acquisition of Merus for $8bn, indicating a strategic shift towards enhancing their pipeline. The company is re-evaluating its drug development focus.
Dec 30, 2025 • AD HOC NEWS
SOMEWHAT-BULLISH
Exact Sciences Corp.: How a Diagnostics Powerhouse Is Rewriting the Cancer Playbook
Exact Sciences Corp. is transforming cancer screening into a software-driven diagnostics platform, making early detection more routine. The company is known for its Cologuard at-home colon cancer screening test and has expanded into multi-cancer early detection and precision oncology. Their strategy focuses on noninvasive screening, precision oncology tools like Oncotype DX, and developing multi-cancer early detection (MCED) via a data-driven approach, positioning them as a critical infrastructure in cancer care.
Dec 30, 2025 • openPR.com
SOMEWHAT-BULLISH
Dementia Drugs Market 2025 Outlook: In-Depth Insights,
The global Dementia Drugs Market is projected to grow from US$26.14 Billion in 2025 to US$41.45 Billion by 2032, exhibiting a CAGR of 6.8%. This growth is driven by increasing industry demand and technological advancements, as highlighted in a new report by Coherent Market Insights. The report provides detailed insights into market dynamics, competitive landscapes, regional analysis, and identifies key companies and growth opportunities within the sector.